Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07172256 · ClinicalTrials.gov registry record · Phase 2
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
A Phase 2 study, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07172256 is a Phase 2 study that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants.
The verdict
NCT07172256, a Phase 2 study, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment naive participants with locally advanced HPV-16 associated head and neck squamous cell carcinoma (HNSCC).
Interventions
- DRUG Pembrolizumab
- DRUG CUE-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05-07 |
| Est. Completion | 2031-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07172256
The ClinicalTrials.gov registry entry for NCT07172256 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07172256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07172256 about?
NCT07172256 is a clinical study titled "CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs". This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment naive participants with locally advanced HPV-16 associated head...
What is the current status of trial NCT07172256?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-05-07. Estimated completion is 2031-02.
What interventions are being tested in trial NCT07172256?
The interventions under investigation include: Pembrolizumab (DRUG), CUE-101 (DRUG).
Who is sponsoring clinical trial NCT07172256?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.